Summary & Overview

HCPCS Level II J0520: Bethanechol Injection, Up to 5 mg

HCPCS Level II code J0520 identifies a therapeutic injection of bethanechol chloride (myotonachol or urecholine), up to 5 mg. Bethanechol is used to stimulate smooth muscle contraction in the bladder and gastrointestinal tract, making this code relevant for clinicians managing urinary retention and certain postoperative or neurogenic hypomotility conditions. Nationally, accurate coding of such injectable agents affects coverage determinations, billing consistency, and claims processing for outpatient and clinic-administered medications.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J0520, common sites of service where the injection is administered, and the typical service type classification. The publication further outlines where to look for payer-specific coverage rules and coding guidance, benchmark considerations for utilization, and related policy updates affecting injectable therapeutic agents.

This summary serves as a national-facing reference for billing staff, clinicians, and policy analysts seeking a clear description of the code, payer scope, and what to expect in terms of administrative and clinical context for J0520 without state-specific variation.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0520HCPCS Level IIbethanecholinjectable-medicationtherapeutic-injectionurinary-retentionoutpatient-carebilling-coding

Billing Code Overview

HCPCS Level II code J0520 represents an injection of bethanechol chloride (myotonachol or urecholine), up to 5 mg. This medication is a parasympathomimetic agent used to stimulate bladder and gastrointestinal smooth muscle contraction.

Service type: Therapeutic injection

Typical site of service: Outpatient clinic, physician office, or ambulatory care setting

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult presenting to an outpatient clinic, emergency department, or surgical recovery area with urinary retention, postoperative urinary atony, or suspected bladder atony where a direct parasympathomimetic agent is indicated to stimulate detrusor muscle contraction. The patient often has a history of recent abdominal or pelvic surgery, spinal cord injury, neurogenic bladder, diabetic autonomic neuropathy, or postoperative anesthesia-related urinary retention. After assessment (history, focused exam, bladder scan or post-void residual), the clinician orders an intramuscular or subcutaneous injection of bethanechol (J0520, up to 5 mg) when catheterization is not immediately indicated or as a trial of pharmacologic bladder stimulation.

Clinical workflow:

Initial evaluation includes vital signs, focused neurologic and abdominal exam, assessment of bladder distention, and review of medications that may contribute to urinary retention.
Bladder volume is measured with a bladder scanner or ultrasound; large retention often prompts catheterization. For moderate retention or suspected detrusor underactivity, bethanechol may be administered.
Consent and allergy review are completed. Medication prepared per medication administration policies; typical route is subcutaneous or intramuscular injection as described in the product labeling for up to 5 mg.
Administer J0520 with monitoring for cholinergic side effects (bradycardia, bronchospasm, hypotension, increased secretions, abdominal cramping). Vital signs are reassessed at intervals post-injection.
If the patient fails to respond or develops complications, urinary catheterization or escalation of care is implemented. Document indication, dose, route, time, response, and any adverse events.

Coding Specifications

Modifier	Description	When to Use
`00`	Default/No modifier specified	Use when no specific modifier applies and the payor accepts no-modifier submissions.

22 | Increased procedural services | Use when work required to administer or manage the medication is substantially greater than typical (rare for simple injection; document justification).

23 | Unusual anesthesia | Use when administration required significant anesthesia beyond local measures (unlikely for this injection; document if applicable).

52 | Reduced services | Use when the planned medication administration was partially reduced or not fully performed.

53 | Discontinued service | Use when the injection was initiated but discontinued due to patient intolerance or acute adverse event.

54 | Surgical care only | Use when the provider bills only the intraoperative component and another provider bills pre/postoperative care (rare for medication injection).

55 | Postoperative management only | Use when only postoperative management is billed by this provider.

56 | Preoperative management only | Use when only preoperative management is billed by this provider.

62 | Two surgeons | Use when two surgeons or proceduralists are required for the procedure (uncommon for this injection).

AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for MHS beneficiaries | Use when service is furnished by advanced practice clinician within Military Health System rules.

CO | Services related to a co-surgery | Use when service is part of coordinated care requiring multiple providers (rare for single injection).

CQ | Service furnished by a registered nurse anesthetist with medical direction by an anesthesiologist | Use only when applicable to anesthesia services accompanying administration.

QX | Qualified non-physician practitioner authorized under Medicare Part B; modifier to identify split/shared or incident-to rules | Use when a non-physician practitioner furnished the service under applicable billing rules.

QY | Medical direction of one CRNA by an anesthesiologist | Use when anesthesiology direction applies to the episode of care.

Taxonomy Code	Specialty	Notes
`363A00000X`	Urology	Urologists commonly evaluate and treat urinary retention and may order or supervise bethanechol administration.

208800000X | Family Medicine | Family physicians in outpatient or urgent care settings may administer this injection for retention management.

207Q00000X | Emergency Medicine | Emergency physicians frequently address acute urinary retention and may use bethanechol as part of initial management.

1835S0201X | Nurse Practitioner | Nurse practitioners in primary, urgent, or specialty settings often provide medication administration and follow-up care.

164W00000X | Physician Assistant | Physician assistants commonly administer medications in procedural and urgent care settings and document clinical response.

OpenPayer